Skip to main content Accessibility help

Clinical Trials Offshored: On Private Sector Science and Public Health

  • Adriana Petryna (a1)


This article addresses the offshoring of clinical trials to middle- and low-income countries, and the complicated ways in which they have become integral to public health and quality of care in these contexts. I focus on the operations of United States-based contract research organizations (CROs), which make up a specialized global industry focusing on the recruitment of human subjects and investigators; they are key players in an outsourced world of clinical development ‘service providers’. To get an on-the-ground understanding of the offshored clinical trial, I worked with regulators, health services administrators, and research clinicians in Eastern Europe and Latin America, two clinical trial market ‘growth regions’. By addressing the strategies of evidence-making that inform clinical trial offshoring, this article identifies the context-specific calculations by which experimental groups are being identified. It also addresses aspects of the clinical trial operational model, in which the failure to predict safety outcomes or a paradigm of expected failure is being exported along with the offshored trial. By highlighting the uncertainties of clinical research, this article points to gaps in systems of human protection as it considers new forms of accountability in private sector science and public health.



Hide All
Abramson, J. (2004). Overdosed America: The broken promise of American medicine. New York: HarperCollins.
Angell, M. (1988). Ethical imperialism? Ethics in international collaborative clinical research. New England Journal of Medicine, 319, 10811083.
Angell, M. (1997). The ethics of clinical research in the Third World. New England Journal of Medicine, 337, 847849.
Angell, M. (2000). Investigators’ responsibilities for human subjects in developing countries. New England Journal of Medicine, 342, 967968.
Angell, M. (2005). The truth about the drug companies: How they deceive us and what to do about it. New York: Random House.
Angell, M. (2006). Your dangerous drugstore. New York Review of Books, 53(10). URL (accessed February 2007):
Avorn, J. (2004). Powerful medicines: The benefits, risks, and costs of prescription drugs. New York: Knopf.
Bayer, R. (1998). The debate over maternal-fetal HIV transmission prevention trials in Africa, Asia, and Caribbean: Racist exploitation or exploitation of racism? American Journal of Public Health, 88, 567570.
Biehl, J. (2001). Technology and affect: HIV/AIDS testing in Brazil. Culture, Medicine and Psychiatry, 25, 87129.
Biehl, J. (2006). Pharmaceutical governance. In Petryna, A.Lakoff, A. & Kleinman, A. (Eds), Global pharmaceuticals: Ethics, markets, practices. Durham, NC: Duke University Press.
Botbol-Baum, M. (2000). The shrinking of human rights: The controversial revision of the Helsinki Declaration. HIV Medicine, 1, 238245.
Christakis, N. (1992). Ethics are local: Engaging cross-cultural variation in the ethics for clinical research. Social Science and Medicine, 35, 10791091.
Cohen, L. (1999). Where it hurts: Indian material for an ethics of organ transplantation. Special issue on ‘Bioethics and beyond’, Daedalus, 128, 135165.
Crouch, R.A., & Arras, J.D. (1998). AZT trials and tribulations. Hastings Center Report, 28, 2634.
Das, V. (1999). Public good, ethics, and everyday life: Beyond the boundaries of bioethics. Special issue on ‘Bioethics and beyond’, Daedalus, 128, 99134.
Das, V., & Das, R.K. (2006). Pharmaceuticals in urban ecologies: The register of the local. In Petryna, A.Lakoff, A. & Kleinman, A. (Eds), Global pharmaceuticals: Ethics, markets, practices. Durham, NC: Duke University Press.
de Zulueta, P. (2001). Randomised placebo-controlled trials and HIV-infected pregnant women in developing countries: Ethical imperialism or unethical exploitation? Bioethics, 15, 289311.
Dickersin, K., & Rennie, D. (2003). Registering clinical trials. Journal of the American Medical Association, 290: 516.
Epstein, S. (1996). Impure science: AIDS, activism, and the politics of knowledge. Berkeley: University of California Press.
Etkin, N. (1999). The rational basis of ‘irrational’ drug use: Pharmaceuticals in the context of development. In Hahn, R.A. (Ed.), Anthropology in public health: Bridging differences in culture and society, 165–182. New York: Oxford University Press.
Farmer, P. (1999). Infections and inequalities: The modern plagues. Berkeley: University of California Press.
Farmer, P. (2002). Can transnational research be ethical in the developing world? The Lancet, 360, 13011302.
FDA (Food and Drug Administration) (2004). Innovation/stagnation: Challenge and opportunity on the critical path to new medical products. March. Washington, DC: Dept of Health & Human Services.
Geertz, C. (2000) [1984]. Anti anti-relativism. In Available light: Anthropological reflections on philosophical topics, 42–67. Princeton, NJ: Princeton University Press.
Goozner, M. (2004). The $800 million pill: The truth behind the cost of new drugs. Berkeley: University of California Press.
Gorman, J. (2004). The altered human is already here. New York Times, 6 April: F1.
Guess, H.A., Kleinman, A., Kusek, J.W., & Engel, L.W. (Eds) (2002). The science of the placebo: Toward an interdisciplinary research agenda. London: BMJ Books.
Harkness, J.M. (1996). Nuremberg and the issue of wartime experiments on US prisoners: The Green Committee. Journal of the American Medical Association, 276, 16721675.
Healy, D. (2003). Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychotherapy and Psychosomatics, 72, 7179.
Juni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P.A., & Egger, M. (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet, 364, 20212029.
Kahn, J.P., Mastroianni, A.C., & Sugarman, J. (1998). Beyond consent: Seeking justice in research. Oxford: Oxford University Press.
Kassirer, J.P. (2004). On the take: How medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press.
Kent, D., Mwamburi, M., Bennish, M., Kupelnick, B., & Ioannidis, J. (2004). Clinical trials in sub-Saharan Africa and established standards of care: A systematic review of HIV, tuberculosis, and malaria trials. Journal of the American Medical Association, 292, 237242.
Kim, J.Y., Mukherjee, J.S., Rich, M.L., Mate, K., Bayona, J., & Becerra, M.C. (2003). From multidrug-resistant tuberculosis to DOTS expansion and beyond: Making the most of a paradigm shift. Tuberculosis, 83, 5965.
Lasagna, L.Prisoner subjects and drug testing. Fed Proc 1977 Sept 36(10): 23492351.
Lemmens, T., & Freedman, B. (1997). Ethics review for sale? Conflict of interest and commercial research ethics review. Milbank Quarterly, 78, 547584.
Lexchin, J., Bero, L.A., Djulbegovic, B., & Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical Journal, 326, 11671170.
Lurie, P., & Wolfe, S.M. (1998). Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. New England Journal of Medicine, 337, 853855.
Lurie, P., & Wolfe, S.M. (2000). Letter to the National Bioethics Advisory Commission regarding their report on the challenges of conducting research in developing countries (HRG Publication #1545). URL (accessed January 2007):
Macklin, R. (1999). Against relativism: Cultural diversity and the search for ethical universals in medicine. Oxford: Oxford University Press.
Marks, H. (1997). The progress of experiment: Science and therapeutic reform in the United States, 1900–1990. Cambridge: Cambridge University Press.
Marks, H. (2000). Where do ethics come from? The role of disciplines and institutions. Paper presented at the Conference on ‘Ethical Issues in Clinical Trials’, University of Alabama at Birmingham, 25 February.
Marks, H. (2002). Commentary. 3rd Annual W.H.R. Rivers Workshop, ‘Global Pharmaceuticals: Ethics, Markets, Practices’, Harvard University, 19– 21 May.
Masters, B., & Kaufman, M. (2004) Painful withdrawal for makers of Vioxx. Washington Post 18 October, A01.
Moynihan, R., & Cassels, A. (2005). Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients. New York: Nation Books.
Office of the Inspector General, Department of Health and Human Services (2001). The globalization of clinical trials: A growing challenge in protecting human subjects. Boston, MA: Office of Evaluation and Inspections.
Petryna, A. (2002). Life exposed: Biological citizens after Chernobyl. Princeton, NJ: Princeton University Press.
Petryna, A. (2005). Ethical variability: Drug development and the globalization of clinical trials. American Ethnologist, 32, 183197.
Petryna, A. (forthcoming) The human subjects research enterprise. Princeton, NJ: Princeton University Press.
Petryna, A., & Kleinman, A. (2006). The pharmaceutical nexus: An introduction. In Petryna, A.Lakoff, A. & Kleinman, A. (Eds), Global pharmaceuticals: Ethics, markets, practices. Durham, NC: Duke University Press.
Rothman, D. (2000). The shame of medical research. New York Review of Books, 47(19), 6064.
Sim, I., & Detmer, D.E. (2005). Beyond trial registration: A global trial bank for clinical trial reporting. PLoS Medicine, 2, e365.
Temple, R. (2002). Placebo-controlled trials and active controlled trials: Ethics and inference. In Guess, H.A.Kleinman, A.Kusek, J.W. & Engel, L.W. (Eds), The science of the placebo: Toward an interdisciplinary research agenda, 209–226. London: BMJ Books.
Wardell, W., & Lasagna, L. (1975). Regulation and drug development. Washington, DC: American Enterprise Institute for Public Policy Research.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

  • ISSN: 1745-8552
  • EISSN: 1745-8560
  • URL: /core/journals/biosocieties
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed